BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23706570)

  • 21. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
    Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
    Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group].
    Móciková H; Marková J; Gahérová Ľ; Král Z; Sýkorová A; Belada D; Procházka V; Martinková L; Papajík T; Kozák T
    Klin Onkol; 2016; 29(5):342-346. PubMed ID: 27739312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma.
    Suzuki K; Terui Y; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Takahashi S; Tsuyama N; Takeuchi K; Hatake K
    Jpn J Clin Oncol; 2013 Jan; 43(1):37-44. PubMed ID: 23166385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
    Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
    Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
    Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS; Greer JP; Goodman S; Brandt SJ; Morgan DS; Macon WR; McCurley TL; Wolff SN
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
    Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
    Ballova V; Ladicka M; Vranovsky A; Lakota J
    Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.
    Rimner A; Lovie S; Hsu M; Chelius M; Zhang Z; Chau K; Moskowitz AJ; Matasar M; Moskowitz CH; Yahalom J
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1066-1076. PubMed ID: 28332991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fundamental approaches to the treatment of refractory and relapsed Hodgkin lymphoma].
    Filatova LV; Tarasenkova AA; Semiglazova TIu; Gershanovich ML
    Vopr Onkol; 2012; 58(4):443-53. PubMed ID: 23607197
    [No Abstract]   [Full Text] [Related]  

  • 40. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
    Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
    Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.